Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship

Gali Epstein-Shochet, Stephen Pham, Steven Beck, Safaa Naiel, Olivia Mekhael, Spencer Revill, Aaron Hayat, Megan Vierhout, Becky Bardestein-Wald, David Shitrit, Kjetil Ask, A. Bruce Montgomery, Martin R. Kolb, Mark W. Surber*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Oral nintedanib is marketed for the treatment of idiopathic pulmonary fibrosis (IPF). While effective slowing fibrosis progression, as an oral medicine nintedanib is limited. To reduce side effects and maximize efficacy, nintedanib was reformulated as a solution for nebulization and inhaled administration. To predict effectiveness treating IPF, the nintedanib pharmacokinetic/pharmacodynamic relationship was dissected. Pharmacokinetic analysis indicated oral-delivered nintedanib plasma exposure and lung tissue partitioning were not dose-proportional and resulting lung levels were substantially higher than blood. Although initial-oral absorbed nintedanib efficiently partitioned into the lung, only a quickly eliminated fraction appeared available to epithelial lining fluid (ELF). Because IPF disease appears to initiate and progress near the epithelial surface, this observation suggests short duration nintedanib exposure (oral portion efficiently partitioned to ELF) is sufficient for IPF efficacy. To test this hypothesis, exposure duration required for nintedanib activity was explored. In vitro, IPF-cellular matrix (IPF-CM) increased primary normal human fibroblast (nHLF) aggregate size and reduced nHLF cell count. IPF-CM also increased nHLF ACTA2 and COL1A expression. Whether short duration (inhalation pharmacokinetic mimic) or continuous exposure (oral pharmacokinetic mimic), nintedanib (1–100 nM) reversed these effects. In vivo, intubated silica produced a strong pulmonary fibrotic response. Once-daily (QD) 0.021, 0.21 and 2.1 mg/kg intranasal (IN; short duration inhaled exposure) and twice-daily (BID) 30 mg/kg oral (PO; long duration oral exposure) showed that at equivalent-delivered lung exposure, QD short duration inhaled nintedanib (0.21 mg/kg IN vs. 30 mg/kg PO) exhibited equivalent-to-superior activity as BID oral (reduced silica-induced elastance, alpha-smooth muscle actin, interleukin-1 beta (IL-1β) and soluble collagen). Comparatively, the increased inhaled lung dose (2.1 mg/kg IN vs. 30 mg/kg PO) exhibited increased effect by further reducing silica-induced elastance, IL-1β and soluble collagen. Neither oral nor inhaled nintedanib reduced silica-induced parenchymal collagen. Both QD inhaled and BID oral nintedanib reduced silica-induced bronchoalveolar lavage fluid macrophage and neutrophil counts with oral achieving significance. In summary, pharmacokinetic elements important for nintedanib activity can be delivered using infrequent, small inhaled doses to achieve oral equivalent-to-superior pulmonary activity.

Original languageEnglish
Article number101933
JournalPulmonary Pharmacology and Therapeutics
StatePublished - Aug 2020


FundersFunder number
Avalyn Pharma
Avalyn Pharma, Inc.
Gilead Sciences
Boehringer Ingelheim
Canadian Pulmonary Fibrosis Foundation
Canadian Institutes of Health Research
Canadian Lung Association


    • IPF
    • Inhalation
    • Nintedanib
    • Pharmacodynamics
    • Pharmacokinetics
    • Silica


    Dive into the research topics of 'Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship'. Together they form a unique fingerprint.

    Cite this